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of the Treg lineage because Treg cells
derived from mice with a disabled
Foxp3 gene express many, but not
all, of the phenotypic and functional
properties of normal Treg cells. Thus,
the signal(s) responsible for the initia-
tion of Treg cell development remains
unknown, and it remains possible
that one result of commitment to the
Treg cell lineage is an increased re-
sistance to negative selection in the
thymus resulting in a population of
Treg cells with a TCR repertoire similar
to Tconv cells but with slightly higher
affinity to self. The self-reactivity might
be below the threshold detectable
in a T cell hybridoma. Although the
studies of Pacholczyk et al. (2007) indi-
cate that the T cells that initiate wast-
ing disease recognize nonself, it is pre-
mature to conclude that the Treg cells
that protect from wasting disease also
exclusively recognize nonself. Self-
specific Treg cells might play a critical
early role in preventing disease by re-
acting to enhanced amounts of self-
peptide MHC class II and mediating
bystander suppression. This model
does not exclude the possibility
that foreign antigen-specific Treg
cells play a complementary role in
protection.
Lastly, one must also consider the
implications of these studies of TCR
repertoire to vaccination. In contrast
to the well-described in vitro anergic
state of Foxp3+ Treg cells, they prolif-
erate and expand as efficiently as do
Tconv cells after in vivo priming. Be-
cause the TCR repertoires of Treg
and Tconv cells are certainly capable
of recognizing any foreign or patho-
gen-derived antigen, it is likely that
vaccination will result in proliferation
of both populations. Because the
marked proliferation of Treg cells in
the tumor-bearing host can be sec-
ondary to their higher affinity for tumor
(self-) antigens, tumor vaccines can re-
sult in further proliferation of the tumor-
specific Treg cells. Manipulation of the
balance between Treg and Tconv cells
in response to vaccination remains
a challenge for the future.
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Crosspriming and crosspresentation are performed by specialized subsets of dendritic cells. In this
issue, Hoeffel et al. (2007) show that human plasmacytoid dendritic cells can crosspresent
HIV-derived peptides conjugated to a lipopeptide or HIV-infected cells undergoing apoptosis.‘‘Exogenous antigens are loaded
onto major histocompatibility complex
(MHC) class II molecules, whereas en-
dogenous antigens are loaded onto
MHC class I molecules’’ is a golden
rule with notable exceptions. Pioneer-
ing work showed that antigen-specific
CD8+ T cells expand in vivowhen small
amounts of exogenous antigen are
delivered together with dead or dy-
ing cells, a phenomenon designatedcrosspriming or crosspresentation for
memory responses. A few years later,
several groups demonstrated that
a small fraction of dedicated dendritic
cells (DCs) within the DEC205+CD8a+
subset performs crosspriming (Bevan,
2006). Since then, the relevance of
crosspriming in immune responseshas
been the subject of extensive investi-
gation. Certainly, extending our knowl-
edge of the key players and molecularImmunity 27, Smechanisms involved in crossprim-
ing and crosspresentation might allow
the experimental manipulation of this
pathway for therapeutic intervention
in cancer and autoimmunity. In this is-
sue of Immunity, Hoeffel et al. (2007)
show that human plasmacytoid DCs
(pDCs) can crosspresent HIV-derived
antigens.
Under steady-state conditions,
crosspresentation provides toleranceeptember 2007 ª2007 Elsevier Inc. 419
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PreviewsFigure 1. Functional Specialization of Human DC Subsets in Crosspresentation of
Exogenous Antigens
Plasmacytoid DCs crosspresent HIV-infected cells undergoing apoptosis to HIV-specific CTLs.
The nature and specificity of the receptor(s) mediating uptake and crosspresentation has yet to
be established. Myeloid DCs crosspresent apoptotic tumor-transformed cells or tumor-derived
antigens offered as immune complexes to antigen-specific CTLs. Immune complexes are taken
up through Fc receptors. Myeloid DCs also efficiently crosspresent soluble antigens targeted to
endocytic receptors, such as DEC205.by inducing peripheral deletion or
anergy of T cells. In contrast, crosspre-
sentation in the context of viral infec-
tion or immunopathology generates
either potent protective or harmful im-
mune responses, respectively. Among
danger signals, type I interferons
(IFN-a/b) have been shown to be cri-
tically involved in crosspriming and
crosspresentation. Because pDCs
(also called interferon-producing cells)
are widely known as professional type
I IFN producers, an ancillary function
of this cell type in crosspriming and
crosspresentation would be expected.
However, the antigen-presenting ca-
pacity of pDCs has long been matter
of debate. Human pDCs can expand
alloreactive T cells or melan A-spe-
cific cytotoxic T lymphocytes (CTLs)
in vitro. They can also polarize prolif-
erating T cells toward T helper 1 (Th1),
Th2, or regulatory T cells, depending
on their activation state. Neverthe-
less, given the high precursor fre-
quency of alloreactive or melan A-spe-
cific T cells, the ability of pDCs to elicit
responses from rare, truly naive
CD4+ or CD8+ T cells remains ques-
tionable.
The identification of murine pDCs
provided the means to rigorously
assess the capacity of these cells to420 Immunity 27, September 2007 ª2007present antigens in vitro and in vivo.
In vitro data indicated that classical
DCs present antigens more efficiently
and elicit more potent T cell responses
than do pDCs. These in vitro results
suggested that pDCs, like B cells, pre-
dominantly induce memory and recall
responses. However, in vivo experi-
ments suggested otherwise: If a solu-
ble antigen is targeted to the pDC
receptor BST-2, murine pDCs can
prime transgenic naive CD4+ T cells
in specific anatomical compartments,
such as peripheral lymph nodes, al-
though they fail to provoke a concomi-
tant specific CD8+ T cell response
(Sapoznikov et al., 2007). Murine pDCs
can also crosspresent soluble antigen
to transgenic T cells in vitro upon CpG
stimulation, a pathway that requires
osteopontin-dependent IFN-a secre-
tion (Shinohara et al., 2006). It should
be noted, however, that the frequency
of naive T cells with a given specificity
in these experiments is unusually high
because TCR transgenic T cells were
used. In fact, pDCs pulsedwith soluble
antigens and activated by CpG fail to
induce substantial expansion of spe-
cific CTLs from rare naive precursor T
cells in vivo, unless antigen is targeted
to a specific endocytic receptor, called
Siglec H, that is expressed on pDCsElsevier Inc.(Zhang et al., 2006). Thus, murine
pDCs can crosspresent, but only in
certain experimental settings—tar-
geted delivery of the antigen, high fre-
quency of T cell precursors, or Toll-like
receptor (TLR)-induced activation with
CpG. Whether these conditions are
frequently met in vivo is unclear.
There is no convincing evidence that
human pDCs can crosspresent anti-
gens. Schnurr et al. demonstrated
that immune complexes of exogenous
melanoma-derived antigens conju-
gated to immunoglobulinsareefficiently
presented to specific CTLs by pri-
mary myeloid DCs but not by pDCs,
even when activated by TLR agonists
(Schnurr et al., 2005). However, in this
issue of Immunity, Hoeffel et al. (2007)
provide experimental evidence that
human pDCs can indeed crosspresent
HIV-derived peptides conjugated to a
lipopetide (a candidate vaccine for HIV
infection), as well as HIV-infected cells
undergoing apoptosis (Figure 1). During
the crosspresentation process, antigen
is taken up in an endosomal compart-
mentmarked by the endocytic receptor
BDCA2 and afterwards localized in low-
acidic vesicles. Surprisingly, in these
experimental settings, pDCs crosspre-
sent antigen as efficiently as domyeloid
DCs.Crosspresentation is enhancedby
stimulation with influenza virus, sug-
gesting that it might be dependent, at
least in part, on type I interferon.
Mechanistically, crosspresentation
by pDCs requires proteasome activity,
indicating that antigen is either pas-
sively delivered or actively transported
into the cytosol for further processing.
The molecular mechanisms that gov-
ern the crosspresentation pathways
in pDCs, as well as the precise nature
of the endosomal compartment in
which crosspresentation occurs, await
future studies. However, because
pDCs have abundant endoplasmic re-
ticulum (ER), it is tempting to speculate
that ER-phagosome fusion might oc-
cur at high rate in pDCs, bringing to-
gether exogenous antigen, the MHC
class I loading machinery and, poten-
tially, proteins involved in the ER-retro-
translocation system, such as the AAA
ATP-ase p97 (Ackerman et al., 2006).
In addition, crosspresentation might
be enhanced in pDCs after stimula-
tion with TLR7 or TLR9 agonists and
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type I interferon might activate NOX2
or other components of the nicotin-
amide adenine dinucleotide phos-
phate (NADPH)-oxidase system,which
produces reactive oxygen intermedi-
ates (ROIs). ROIs reduce endosomal
pH, which in turn prevents complete
degradation of the antigen and thereby
enhances antigen crosspresentation
(Savina et al., 2006). Although human
pDCs do not express mannose re-
ceptor, a C type lectin that favors
crosspresentation by enabling antigen
uptake into specialized endosomes
(Burgdorf et al., 2007), they might em-
ploy other mechanisms of receptor-
mediated endocytosis to crosspresent
antigens. This phenomenon could also
explain the discrepancy between the
crosspresentation of HIV peptide-lipo-
peptide conjugates and HIV-infected
apoptotic cells observed in the present
study, and the lack of crosspresenta-
tion of tumor antigens or tumor anti-
gens delivered as immune complexes
(Figure 1). It is likely that, depending
on the receptor selectively engaged,
the antigen reaches different compart-Why Is There so
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The balance between kinases a
this issue, McNeill et al. (2007)
both positive and negative regul
The presence of CD45 molecules on
hematopoietic cells has long been an
enigma: Why so much, why so big,
why so variable, why can we not find
a ligand? One of the most abundant
molecules on the lymphocyte surface,
CD45 was identified a number of years
ago as a transmembrane phosphatase
(Hermiston et al., 2003). The large ex-
tracellular domain of CD45 is notable
for its highly glycosylated and sialy-ments and undergoes complete deg-
radation and exclusive loading onto
MHC class II or partial degradation
and further processing into the cytosol
for loading intoMHCclass I molecules.
Accordingly, myeloid DCs are more
efficient at crosspresenting HIV-gag
protein when it is targeted to human-
DEC205 receptor than when it is tar-
geted to a closely related receptor
like DC-SIGN (Bozzacco et al., 2007).
Hoeffel et al. have returned pDCs to
the center stage of antigen presenta-
tion. Clearly, it is essential to determine
whether crosspresentation by human
pDCs is a common event, especially
during HIV infection, and whether such
presentation leads to T cell stimulation
or T cell anergy in vivo. Because HIV
does not productively infect pDCs, but
activates them through TLR7, cross-
presentation by pDCs might be a very
effective way to elicit anti-HIV T cell
responses.
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lated state, which varies depending
on the inclusion or exclusion of alter-
natively spliced exons 4, 5, and 6.
The resulting isoforms are specific
not only to hematopoietic cell type,
but also to the stage of differentiation
and activation of the cell. Not surpris-
ingly, therefore, it was suggested that
these alternative isoforms might inter-
act with unique ligands; however, con-
vincing identification of ligands spe-
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ulating lymphocyte signaling. In
osphatase CD45 has a role as
cific for any of the isoforms has so far
defied a seemingly endless supply of
research dollars and several lifespans
of graduate students.
The major intracellular targets of
CD45 phosphatase activity are the
Src-family kinases (SFK), which in T
cells are predominantly the family
members p56Lck (Lck) and p59Fyn
(Fyn). Lck, in particular, is a primary
initiator of signal transduction upon
eptember 2007 ª2007 Elsevier Inc. 421
